Alzheimer’s disease typically presents with impaired cognition and pathological morphologic changes, including the accumulation of amyloid-
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders
characterized by impairments of cognitive function [1]. The dominant pathological
hallmarks of AD include aggregated amyloid-
The amyloid-
Paeonol is an herbal compound obtained from the
Moutan cortex of Paeonia suffruticosa Andrews, found to possess various
therapeutic pharmacological and biological properties [10]. A number of studies
indicate that paeonol exerts multiple effects in the control of tissue
homeostasis and the modulation of inflammatory mechanisms, with the potential to
ameliorate neuronal damage [11, 12, 13]. This suggests a potential neuroprotective
role of paeonol in AD. Though previous studies have explored the neuroprotective
role of paeonol [13, 14], it remains unknown whether it could be beneficial in
AD. Hence, we performed an in vivo study of paeonol in a genetic rodent
AD model. In order to reveal paeonol’s therapeutic
effect on A
APP/PS1 (APPswe, PSEN1dE9) double transgenic mice and their age matched
wild-type (WT) littermates were purchased from Beijing Vital River Laboratory
Animal Technology Co., Ltd. (Beijing, China). Mice were housed in specific
pathogen free laboratory conditions with no more than four per cage. The mice
were housed with controlled temperature (22–24
The MWM test is a hippocampus-dependent cognitive memory task assessed in an open field water maze as previously described [5]. The mice were trained to escape from the water by locating a hidden escape platform submerged approximately 1 cm below the water surface at a fixed location. The platform was located at the center of one of the four quadrants of the pool. Training consisted of 4 trials per day for 5 days. On day 6 of testing, the platform was removed and the mice were allowed to swim freely to explore the pool. The swimming parameters were recorded and calculated with a camera connected to a behavioral monitoring system (Noldus Information Technology, Wageningen, the Netherlands).
The object recognition test was performed in a square box under low light levels [17]. Mice were first habituated to the empty arena for 10 min per day for 3 days prior to the object recognition test. For the sampling phase, 2 identical objects were placed at 2 adjacent corners of the box, and the mice were allowed to explore freely in the box for 10 min. After 24 h, mice were reintroduced to the arena for 10 min for the test phase. During this test phase, the arena contained one object identical to those used in the sampling phase, and one novel object. The time spent exploring each object was recorded. A discrimination score was provided by calculating the time spent exploring the novel object minus the time spent exploring the familiar object, and dividing this by the total time spent exploring both novel and familiar objects during the test phase. The arena and objects were wiped down with 70% ethanol between trials to minimize olfactory cues. Ethovision XT (Noldus, Wageningen, Netherlands) was used to track the mice during testing.
After the brain sections were permeabilized with 0.3% Triton X-100 and blocked
in 5% BSA, Thioflavin S (Thio S) staining was performed as previously described
[18]. The hippocampal sections were immersed in Thio S
solution (1%, 8 min) for staining. After washing, brain images were captured
with a Nikon microscope. A
After mice were deeply anesthetized with isoflurane, the cortex and hippocampus
brains tissues were quickly dissected and homogenized. After the homogenate was
centrifuged, the supernatants were collected and the samples used to measure
TNF-
Stereotaxic surgery and adeno-associated virus (AAV) injection were performed as previously described [19]. Mice were placed on a stereotaxic apparatus (RWD science, Shenzhen, China) under isoflurane anesthesia, and a solution containing AAV-GFP was delivered to CA1 region: AP –1.8 mm; ML 1.25 mm; DV –1.25 mm in 100 nL doses. Infusions were performed at a rate of 20 nL/min. Spines of GFP-labeled neurons could be clearly visualized after a two-week recovery period.
Hippocampus tissue sections (400
Dissected hippocampi were harvested and lysed using RIPA buffer containing
protease and phosphatase inhibitors (Beyotime, China). The concentration of
protein was measured with a BCA protein assay kit (Pierce, Rockford, USA). Later,
equal amounts of protein were separated by SDS-PAGE and transferred to PVDF
membranes (BioRad). After blocking with 5% skimmed milk for 2 h at room
temperature, they were incubated overnight at 4
After being perfused transcardially with ice-cold 0.1 M phosphate-buffered
saline (PBS) and post fixed with 4% paraformaldehyde (PFA) [20],
4-
Data in this study were analyzed using GraphPad Prism 7.0 software (GraphPad
Inc., La Jolla, CA, USA) and results are shown as
mean
Impaired cognitive performance is well observed in the APP/PS1 AD model. After paeonol or vehicle treatment, the behavior of the three groups were tested using the Morris Water Maze (MWM) and novel object recognition (NOR). In the MWM, the results showed that the paeonol treated APP/PS1 mice took less time to reach the hidden platform than the vehicle-treated APP/PS1 mice during the training phase (Fig. 1A,B). The average swimming speed did not differ among the three groups. In the following probe trials, the APP/PS1 mice explored a shorter time, as well as performing fewer crossings into the target quadrant than the WT group. However, both parameters were significantly improved by paeonol treatment (Fig. 1C,D). In the NOR test, as expected, vehicle-APP/PS1 mice could not distinguish the novel from the familiar object, while paeonol-treat APP/PS1 mice displayed a significantly higher discrimination index, with better cognitive performance (Fig. 1E,F).
Paeonol improves neurobehavioral outcomes in APP/PS1 transgenic
mice. (A) The time to climb on the hidden platform during the training phase of
Morris water maze. (B) Trace map of the mice during the Morris water maze test.
(C) The time of exploring hidden platform in the Morris water maze. (D) The
number of crossing hidden platform in the Morris water maze. (E) Time of
exploring same object in the novel object test. (F) Recognition index performance
in the novel object test. Mean
After behavioral testing, the mice were sacrificed, and A
Paeonol adminstration decreased A
We carried out Iba1 immunofluorescence staining to assess whether paeonol could
inhibit microglial activation in APP/PS1 mice. Results showed that the activation
of microglia in the hippocampus of paeonol-treated mice were inhibited compared
with vehicle-treated APP/PS1 mice (Fig. 3A) and this was further confirmed by
immunoblot analysis (Fig. 3B). We also studied the effects of paeonol on the
expression of inflammation-related molecules in the cortex and hippocampus of
APP/PS1 mice, with levels of TNF-
Paeonol treatment caused microglia inactivation and decreased
neuroinflammation in APP/PS1 mice. (A) Immunohistochemistry for microglia
markers ionized calcium-binding adapter molecule 1 (Iba1) in the hippocampus.
Scale bars, 20
Previous results prompted us to further evaluate hippocampus neural damage. According to the results of Nissl staining, the decreased number of Nissl-positive cells within CA1 and CA3 hippocampal subregions revealed a significant protective effect of paeonol (Fig. 4A). It was proved that APP/PS1 mice administered paeonol exhibited a significantly decreased proportion of Nissl-positive cells (Fig. 4B). This provides direct evidence that paeonol confers a neuroprotective effect. APP/PS1 mice have been shown to undergo spine morphology changes and decreases in spine density. To examine whether paeonol treatment achieved a therapeutic effect on synaptic connectivity, hippocampal neuronal spines from each group were GFP-labelled for morphological analysis (Fig. 4C). Spine loss was represented by diminished GFP-labelling, and this was observed in the hippocampus pyramidal neurons of APP/PS1 mice. Paeonol administration reversed this spine density reduction, implying a neuroprotective effect of paeonol on synaptic impairment (Fig. 4D).
Paeonol treatment inhibited neuronal damage in the hippocampus
of APP/PS1 mice. (A) Nissl staining results of the hippocampal
CA1 and CA3 regions. (B) Quantification of
Nissl-positive dead cells in the hippocampus of CA1 and CA3 regions. (C)
Representative photomicrographs of EGFP-labeling in CA1 neurons under treatment
with Paeonol. Scale bar: 10
Long-term potentiation (LTP) was induced within the hippocampus to test the hypothesis that paeonol improves cognitive recovery by rescuing functional synaptic connections in this brain region in APP/PS1 mice. The slope of field excitatory postsynaptic potential (fEPSP) induced by stimulation was calculated in each study group. Paeonol could effectively rescue excitatory synaptic current deficit in APP/PS1 mice after the high-frequency stimulation protocol, as demonstrated in the improved LTP found in paeonol-treated mice (Fig. 5A,B). The expression of molecular markers of synaptic damage was further examined. As shown in Fig. 5C–F, we observed that compared with controls APP/PS1 mice, the levels of post-synaptic protein-95 (PSD-95), synaptophysin (SYN), and dendritic-related molecular microtubule-associated protein-2 (MAP-2) were significantly increased in mice receiving paeonol treatment. These molecular expression findings further validate the synaptic protection of paeonol witnessed in functional performance tests.
Paeonol administration promote synaptic plasticity in APP/PS1
mice. (A) Traces of hippocampal LTP induced with high frequency stimulation. (B)
Normalized fEPSP slopes of HFS-induced LTP. (C–F) Representative immunoblots and
the relative levels of PSD-95, SYP, and MAP-2. Mean
As the major contributor to dementia, memory and cognitive impairment are the
two prominent features of AD [22]. There is an urgent need to develop novel
effective preventative treatments that are accompanied by minimal adverse
effects. In this study, we utilized a rodent AD model to assess the potential
protective effects of paeonol against AD-like behavioral and pathological
manifestations. Our results provide evidence that paeonol exerts a therapeutic
effect in APP/PS1 mice. Paeonol treatment for 3 weeks effectively prevented high
A
To attain confirmation of the effects of paeonol on APP/PS1 mice while considering the 3R principle, only males were tested in this study. In the hippocampus-dependent memory MWM test, paeonol-treated APP/PS1 mice showed enhanced learning compared to their vehicle-treated counterparts. Indeed, both groups of mice could learn to locate the platform position within several days. However, paeonol-treated APP/PS1 mice showed a faster learning curve, achieving a significant improvement by the end of the learning period. In another hippocampus-dependent cognitional behaviors test, the NOR test, paeonol-treated APP/PS1 mice spent more time investigating the novel object, which further confirmed our hypothesis that paeonol has an effect on AD. This is well in agreement with previous studies’ reports that this compound can improve learning behavior in rodent brain disease models [13, 14].
APP overexpression has been shown to be a central mediator of microglia
activation in the pathogenesis of AD [23]. Amyloid plaques deposited in the AD
brain are closely associated with a local inflammatory process, with
neuroinflammation a key factor contributing to the further production of
A
The hippocampus is one of the main areas of the brain affected by neuronal
injury and synaptic plasticity in AD.
Previous studies have shown that A
In summary, we showed that paeonol could reverse cognitive impairment and
A
AD, Alzheimer’s disease; A
SXM conceived and designed the experiments; BW performed the experiments; WL analyzed the data; WL contributed reagents and materials; SXM wrote the paper.
Animals were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) and raised and handled at the Laboratory Animal Center of the Shanghai Jiao Tong University. All animal experiments were carried out in accordance with the guidelines of the Guidelines for Animal Care and Use of China, and the experimental schemes were approved by the animal ethics committee of Shanghai Jiao Tong University (SYXK-2020-0050).
We thank three anonymous reviewers for excellent criticism of the article.
This study was supported by Project of Shanghai Science and Technology Commission (19401970600); Project of Shanghai Science and Technology Commission (19401932500).
The authors declare no conflict of interest.